drugset / Trial / NCT01916447
A Phase I Study of TAS-102 in Patients With Advanced Gastrointestinal Tumors.
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to investigate the safety and determine the maximum tolerated dose of TAS-102 administered in combination with CPT-11 in patients with advanced gastrointestinal tumors.
Timeline
- Start
- 2013-09
- Primary completion
- 2017-09
- Completion
- 2017-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 5 mg/kg | Intravenous |
| Subject | Irinotecan | Small molecule | 120 mg/m2 | Intravenous |
| Subject | Irinotecan | Small molecule | 180 mg/m2 | Intravenous |
| Subject | TAS-102 | Small molecule | 20 mg/m2 | Oral |
| Subject | TAS-102 | Small molecule | 35 mg/m2 | Oral |
Indications
No indication recorded.